Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present BioLineRx Ltd. (NASDAQ: BLRX).

Full DD Report for BLRX

You must become a subscriber to view this report.


Recent News from (NASDAQ: BLRX)

BioLineRx to Present Overall Survival Data at EHA from Phase 2a Study of BL-8040 in r/r AML Patients
TEL AVIV, Israel , May 17, 2018 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that it will present data at the 23rd Annual Congress of the European Hematology Association (EHA) ...
Source: PR Newswire
Date: May, 17 2018 09:15
Breakfast Technical Briefing on BioLine Rx and Three More Biotech Stocks
Stock Research Monitor: PETX, BCRX, and BDSI LONDON, UK / ACCESSWIRE / May 17, 2018/ If you want a free Stock Review on BLRX sign up now at www.wallstequities.com/registration . In today's pre-market research, WallStEquities.com evaluates Aratana Therapeutics Inc. (NASDAQ: PETX ), Bi...
Source: ACCESSWIRE IA
Date: May, 17 2018 09:00
BioLineRx Reports Results of Phase 2 Study for BL-8040 Monotherapy in Stem Cell Mobilization for Allogeneic Bone Marrow Transplantation
TEL AVIV, Israel , May 17, 2018 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today positive results from a Phase 2 clinical trial assessing BL-8040 as a single agent for hematopoietic s...
Source: PR Newswire
Date: May, 17 2018 09:00
BioLineRx to Report First Quarter 2018 Results on May 22, 2018
TEL AVIV, Israel , May 16, 2018 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX)( TASE: BLRX)( BLRX) , a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today it will release its unaudited financial results for the quarter ended March 31, 2018 on ...
Source: PR Newswire
Date: May, 16 2018 08:00
BioLineRx Announces Grant of European Patent Covering Use of BL-8040 with Cytarabine for Treating Acute Myeloid Leukemia
TEL AVIV, Israel , May 16, 2018 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX)(TASE: BLRX)( BLRX) , a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that the European Patent Office (EPO) has issued a Decision to Grant a patent claiming the u...
Source: PR Newswire
Date: May, 16 2018 07:00
How To Play 'Am I Diversified?' In The Pharma/Biotech Space
Background Many investors (including myself) regularly watch or listen to the show "Mad Money" by Jim Cramer on CNBC. As with any celebrity, Mr. Cramer tends to be polarizing, with some loving him and some reveling in pointing out when he is wrong. Rather than focusing on his individual stoc...
Source: SeekingAlpha
Date: May, 03 2018 00:54
Wired News - vTv Therapeutics Completed Phase-1b Study Evaluating TTP399 for Treatment of Type-1 Diabetes
Stock Monitor: BioLine Rx Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 27, 2018 / Active-Investors.com has just released a free research report on vTv Therapeutics Inc. (NASDAQ: VTVT ). If you want access to this report all you need to do is sign up now by clicking the fol...
Source: ACCESSWIRE IA
Date: March, 27 2018 07:20
BioLineRx Announces Notice of Allowance From USPTO for Patent Covering AGI-134 - a Novel Immunotherapy for Treating Solid Tumors
TEL AVIV, Israel , March 26, 2018 /PRNewswire/ --  BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that a Notice of Allowance has been issued by the United States Patent and Trademark Office...
Source: PR Newswire
Date: March, 26 2018 07:00
Key events next week - healthcare (continued #1)
Tuesday (3/20): Oppenheimer (continued). BioLineRx (NASDAQ: BLRX ); Aerie Pharmaceuticals (NASDAQ: AERI ); United Therapeutics (NASDAQ: UTHR ); Addus HomeCare (NASDAQ: ADUS ); Centene (NYSE: CNC ); Quorum Health (NYSE: QHC ); Pfenex (NYSEMKT: PFNX ); SELLAS Life Sciences (NASDAQ: SLS...
Source: SeekingAlpha
Date: March, 16 2018 10:26
BioLineRx to Present at the 28th Annual Oppenheimer Healthcare Conference
TEL AVIV, Israel , March 14, 2018 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that its Chief Executive Officer, Philip Serlin , will present a company update at the 28...
Source: PR Newswire
Date: March, 14 2018 07:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-08-170.9050.8860.90990.8869,097
2018-08-160.8750.88640.9096990.8701189,623
2018-08-150.900.8750.900.875233,186
2018-08-140.9250.88690.9250.875523,306
2018-08-130.890.9063690.9480.871,187,065

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-171,82414,89212.2482Cover
2018-08-1643,616120,08436.3212Short
2018-08-1531,38484,79537.0116Short
2018-08-1465,130186,43934.9337Cover
2018-08-13247,545519,27347.6715Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on BLRX.


About BioLineRx Ltd. (NASDAQ: BLRX)

Logo for BioLineRx Ltd. (NASDAQ: BLRX)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: BLRX)

      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: May, 17 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: May, 17 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: May, 16 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: April, 24 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: April, 24 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: April, 16 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: April, 16 2018
      Filing Type: CT ORDERFiling Source: edgar
      Filing Date: April, 02 2018
      Filing Type: CT ORDERFiling Source: edgar
      Filing Date: April, 02 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: March, 26 2018

       

       


      Daily Technical Chart for (NASDAQ: BLRX)

      Daily Technical Chart for (NASDAQ: BLRX)


      Stay tuned for daily updates and more on (NASDAQ: BLRX)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: BLRX)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      DD Report
      @DDReports

       

       


      Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in BLRX is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of BLRX and does not buy, sell, or trade any shares of BLRX. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/